Literature DB >> 19486015

Microtubule-interacting drugs induce moderate and reversible damage to human bone marrow mesenchymal stem cells.

H Polioudaki1, M-C Kastrinaki, H A Papadaki, P A Theodoropoulos.   

Abstract

OBJECTIVES: This study aimed to investigate molecular and cellular changes induced in human bone marrow mesenchymal stem cells (hMSCs) after treatment with microtubule-interacting agents and to estimate damage to the bone marrow microenvironment caused by chemotherapy.
MATERIALS AND METHODS: Using an in vitro hMSC culture system and biochemical and morphological approaches, we studied the effect of nocodazole and taxol(R) on microtubule and nuclear envelope organization, tubulin and p53 synthesis, cell cycle progression and proliferation and death of hMSCs isolated from healthy donors. RESULTS AND
CONCLUSIONS: Both nocodazole and taxol reduced hMSC proliferation and induced changes in the microtubular network and nuclear envelope morphology and organization. However, they exhibited only a moderate effect on cell death and partial arrest of hMSCs at G(2) but not at M phase of the cell cycle. Both agents induced expression of p53, exclusively localized in abnormally shaped nuclei, while taxol, but not nocodazole, increased synthesis of beta-tubulin isoforms. Cell growth rates and microtubule and nuclear envelope organization gradually normalized after transfer, in drug-free medium. Our data indicate that microtubule-interacting drugs reversibly inhibit proliferation of hMSCs; additionally, their cytotoxic action and effect on microtubule and nuclear envelope organization are moderate and reversible. We conclude that alterations in human bone marrow cells of patients under taxol chemotherapy are transient and reversible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19486015      PMCID: PMC6495966          DOI: 10.1111/j.1365-2184.2009.00607.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  45 in total

1.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray.

Authors:  Nicoletta Bertani; Paolo Malatesta; Giorgia Volpi; Paolo Sonego; Roberto Perris
Journal:  J Cell Sci       Date:  2005-08-09       Impact factor: 5.285

3.  Increased caveolin-1, a cause for the declined adipogenic potential of senescent human mesenchymal stem cells.

Authors:  Jeong-Soo Park; Hee-Young Kim; Hyang-Won Kim; Gi-Nam Chae; Hyung-Tae Oh; Jin-Young Park; Hosup Shim; Min Seo; Eun-Young Shin; Eung-Gook Kim; Sang Chul Park; Sahng-June Kwak
Journal:  Mech Ageing Dev       Date:  2005-01-18       Impact factor: 5.432

4.  Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction.

Authors:  Lutz P Mueller; Jana Luetzkendorf; Thomas Mueller; Katrin Reichelt; Heike Simon; Hans-Joachim Schmoll
Journal:  Stem Cells       Date:  2006-08-24       Impact factor: 6.277

5.  Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis.

Authors:  P J Moos; F A Fitzpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer.

Authors:  C A Jamis-Dow; R W Klecker; G Sarosy; E Reed; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Synthesis and antitumor activity of peptide-paclitaxel conjugates.

Authors:  Serafim Papas; Tonia Akoumianaki; Christos Kalogiros; Lazaros Hadjiarapoglou; Panayiotis A Theodoropoulos; Vassilios Tsikaris
Journal:  J Pept Sci       Date:  2007-10       Impact factor: 1.905

8.  Drugs affecting microtubule dynamics increase alpha-tubulin mRNA accumulation via transcription in Tetrahymena thermophila.

Authors:  L A Stargell; D P Heruth; J Gaertig; M A Gorovsky
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

9.  Shared actions of endotoxin and taxol on TNF receptors and TNF release.

Authors:  A H Ding; F Porteu; E Sanchez; C F Nathan
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

10.  Autogenous regulation of tubulin synthesis via RNA stability during sea urchin embryogenesis.

Authors:  Z Y Gong; B Brandhorst
Journal:  Development       Date:  1988-01       Impact factor: 6.868

View more
  9 in total

Review 1.  Cytoskeletal and focal adhesion influences on mesenchymal stem cell shape, mechanical properties, and differentiation down osteogenic, adipogenic, and chondrogenic pathways.

Authors:  Pattie S Mathieu; Elizabeth G Loboa
Journal:  Tissue Eng Part B Rev       Date:  2012-08-06       Impact factor: 6.389

2.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.

Authors:  Ana Livia Silva Galbiatti-Dias; Glaucia Maria Mendonça Fernandes; Marcia Maria Urbanin Castanhole-Nunes; Luiza Fernandes Hidalgo; Carlos Henrique Viesi Nascimento Filho; Rosa Sayoko Kawasaki-Oyama; Leticia Antunes Muniz Ferreira; Patricia Matos Biselli-Chicote; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity.

Authors:  Hong Lin; Elisa de Stanchina; Xi Kathy Zhou; Feng Hong; Andrew Seidman; Monica Fornier; Wei-Lie Xiao; Edward J Kennelly; Kathleen Wesa; Barrie R Cassileth; Susanna Cunningham-Rundles
Journal:  Cancer Immunol Immunother       Date:  2010-02-06       Impact factor: 6.968

4.  Behavioral abnormalities in prion protein knockout mice and the potential relevance of PrP(C) for the cytoskeleton.

Authors:  Matthias Schmitz; Saima Zafar; Christopher J Silva; Inga Zerr
Journal:  Prion       Date:  2014       Impact factor: 3.931

5.  Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.

Authors:  Augusto Pessina; Arianna Bonomi; Valentina Coccè; Gloria Invernici; Stefania Navone; Loredana Cavicchini; Francesca Sisto; Maura Ferrari; Lucia Viganò; Alberta Locatelli; Emilio Ciusani; Graziella Cappelletti; Daniele Cartelli; Caruso Arnaldo; Eugenio Parati; Giovanni Marfia; Roberto Pallini; Maria Laura Falchetti; Giulio Alessandri
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

6.  Human mesenchymal stem cells are resistant to Paclitaxel by adopting a non-proliferative fibroblastic state.

Authors:  Dale B Bosco; Rachael Kenworthy; Diego A R Zorio; Qing-Xiang Amy Sang
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

7.  Substrate stiffness regulates solubility of cellular vimentin.

Authors:  Maria E Murray; Melissa G Mendez; Paul A Janmey
Journal:  Mol Biol Cell       Date:  2013-10-30       Impact factor: 4.138

8.  Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy.

Authors:  Alessandra Maria Calogero; Mariele Viganò; Silvia Budelli; Daniela Galimberti; Chiara Fenoglio; Daniele Cartelli; Lorenza Lazzari; Petri Lehenkari; Margherita Canesi; Rosaria Giordano; Graziella Cappelletti; Gianni Pezzoli
Journal:  J Cell Mol Med       Date:  2018-03-04       Impact factor: 5.310

9.  Characterization of Signalling Pathways That Link Apoptosis and Autophagy to Cell Death Induced by Estrone Analogues Which Reversibly Depolymerize Microtubules.

Authors:  Anne E Mercier; Renaud Prudent; Michael S Pepper; Leanne De Koning; Elsie Nolte; Lauralie Peronne; Marcel Nel; Laurence Lafanechère; Anna M Joubert
Journal:  Molecules       Date:  2021-01-29       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.